Compare ESPR & MCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | MCS |
|---|---|---|
| Founded | 2008 | 1935 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.9M | 590.8M |
| IPO Year | 2013 | 1994 |
| Metric | ESPR | MCS |
|---|---|---|
| Price | $1.90 | $18.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $8.75 | ★ $23.33 |
| AVG Volume (30 Days) | ★ 7.4M | 125.7K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.72% |
| EPS Growth | ★ 60.71 | N/A |
| EPS | N/A | ★ 0.77 |
| Revenue | $403,135,000.00 | ★ $758,458,000.00 |
| Revenue This Year | N/A | $12.05 |
| Revenue Next Year | $12.81 | $3.15 |
| P/E Ratio | ★ N/A | $24.18 |
| Revenue Growth | ★ 21.31 | 3.11 |
| 52 Week Low | $0.73 | $12.85 |
| 52 Week High | $4.18 | $20.02 |
| Indicator | ESPR | MCS |
|---|---|---|
| Relative Strength Index (RSI) | 31.41 | 56.58 |
| Support Level | $1.34 | $14.66 |
| Resistance Level | $2.08 | $20.02 |
| Average True Range (ATR) | 0.16 | 0.55 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 11.89 | 30.89 |
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.